Key facts
- This page summarizes Robert E. Gagnon's Form 4 filing for Bone Biologics Corp (BBLG).
- 1 reported transaction and 4 derivative rows are listed below.
- Accepted by SEC: 06 Jun 2025, 17:01.
Robert E. Gagnon - 04 Jun 2025 Form 4 Insider Report for Bone Biologics Corp (BBLG)
- Reporting relationship
- Director
- Issuer ticker
- BBLG
- Reported as of
- 04 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jun 2025, 17:01:12 UTC
- Prior SEC filing
- 27 May 2025
- Next SEC filing
- 20 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert E. Gagnon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Gagnon filed Form 4 for Bone Biologics Corp (BBLG) on 06 Jun 2025.
Change
- Previous filing in this sequence was filed on 27 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001504983
Primary reporting owner
Gagnon Robert E.
- Relationship
- Director
- Address
- C/O BONE BIOLOGICS CORP,, 2 BURLINGTON WOODS DR. SUITE 100, BURLINGTON,
- Signature
- /s/ Robert E. Gagnon
- Signature date
- 06 Jun 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBLG
transaction
Derivative
Non-Employee Stock Option
Award
- Transaction value
- $0
- Shares
- +62,894
- Change %
- Price
- $0.000000
- Shares after
- 62,894
- Date
- 04 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 62,894
- Exercise price
- $0.8800
- Footnotes
- F1
BBLG
holding
Derivative
Non-Employee Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 30,713
- Date
- 04 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,713
- Exercise price
- $1.73
- Footnotes
- F2
BBLG
holding
Derivative
Non-Employee Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9
- Date
- 04 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9
- Exercise price
- $4.68
- Footnotes
- F3
BBLG
holding
Derivative
Non-Employee Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,006
- Date
- 04 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,006
- Exercise price
- $4.68
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.
Footnote F2
This option was granted on 9/17/2024 and vests in four equal quarterly installments.
Footnote F3
This option is fully exercisable as of the date of this report.